In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis

Clinical Immunology

Volumn 106, Issue 3, 2003, Pages 163-174

  Schmied, M ^a,b   Duda, P W ^a,c   Krieger, J I ^a   Trollmo, C ^a   Hafler, D A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Anergy; Copaxone; Multiple sclerosis

Indexed keywords

GLATIRAMER; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; CROSS REACTION; DILUTION; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE SCLEROSIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RELAPSE; REMISSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0037357642     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(03)00020-2     Document Type: Article

References (45)

1. Martin R., McFarland H.F. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit. Rev. Clin. Lab. Sci. 32:1995;121-182.
2. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., Schiffer R.B., Vollmer T., Weiner L.P., Wolinsky J.S. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer I Multiple Sclerosis Study Group. Neurology. 50:1998;701-708.
3. Mancardi G.L., Sardanelli F., Parodi R.C., Melani E., Capello E., Inglese M., Ferrari A., Sormani M.P., Ottonello C., Levrero F., Uccelli A., Bruzzi P. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology. 50:1998;1127-1133.
4. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R., Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1:1971;242-248.
5. Teitelbaum D., Fridkis-Hareli M., Arnon R., Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64:1996;209-217.
6. Ben-Nun A., Mendel I., Bakimer R., Fridkis-Hareli M., Teitel-baum D., Arnon R., Sela M., Kerlero de Rosbo N. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic effect of copolymer 1 on MOG-induced disease . J. Neurol. 243:1996;S14-22.
7. Fridkis-Hareli M., Teitelbaum D., Gurevich E., Pecht I., Brautbar C., Kwon O.J., Brenner T., Arnon R., Sela M. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - Specificity and promiscuity. Proc. Natl. Acad. Sci. USA. 91:1994;4872-4876.
8. Racke M.K., Quigley L., Cannella B., Raine C.S., McFarlin D.E., Scott D.E. Superantigen modulation of experimental allergic encephalomyelitis activation of anergy determines outcome . J. Immunol. 152:1994;2051-2059.
9. Teitelbaum D., Milo R., Arnon R., Sela M. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc. Natl. Acad. Sci. USA. 89:1992;137-141.
10. Aharoni R., Teitelbaum D., Sela M., Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J. Neuroimmunol. 91:1998;135-146.
11. Fridkis-Hareli M., Teitelbaum D., Arnon R., Sela M. Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells. Cell. Immunol. 163:1995;229-236.
12. Fridkis-Hareli M., Strominger J.L. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J. Immunol. 160:1998;4386-4397.
13. Fridkis-Hareli M., Aharoni R., Teitelbaum D., Arnon R., Sela M., Strominger J.L. Binding of random copolymers of three amino acids to class II MHC molecules. Int. Immunol. 11:1999;635-641.
14. Fridkis-Hareli M., Teitelbaum D., Pecht I., Arnon R., Sela M. Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells. Int. Immunol. 9:1997;925-934.
15. Brosnan C.F., Litwak M., Neighbour P.A., Lyman W.D., Carter T.H., Bornstein M.B., Bloom B.R. Immunogenic potentials of copolymer I in normal human lymphocytes. Neurology. 35:1985;1754-1759.
16. Duda P.W., Schmied M.C., Cook S.L., Krieger J.I., Hafler D.A. Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105:2000;967-976.
17. Farina C., Vargas V., Heydari N., Kumpfel T., Meinl E., Hohlfeld R. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J. Neuroimmunol. 123:2002;188-192.
18. Neuhaus O., Farina C., Yassouridis A., Wiendl H., Then Bergh F., Dose T., Wekerle H., Hohlfeld R. Multiple sclerosis comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells . Proc. Natl. Acad. Sci. USA. 97:2000;7452-7457.
19. Gran B., Tranquill L.R., Chen M., Bielekova B., Zhou W., Dhib-Jalbut S., Martin R. Mechanisms of immunomodulation by glatiramer acetate. Neurology. 55:2000;1704-1714.
20. Dabbert D., Rosner S., Kramer M., Scholl U., Tumani H., Mader M., Weber F. Glatiramer acetate (copolymer-1) specific, human T cell lines cytokine profile and suppression of T cell lines reactive against myelin basic protein . Neurosci. Lett. 289:2000;205-208.
21. Qin Y., Zhang D.Q., Prat A., Pouly S., Antel J. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J. Neuroimmunol. 108:2000;201-206.
22. Zhang J., Markovic-Plese S., Lacet B., Raus J., Weiner H.L., Hafler D.A. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179:1994;973-984.
23. C. Henry, J. Marbrook, D.C. Vann, D. Kodlin, C. Wofsy, Limiting dilution analysis, in: Mishell, Shigii (Eds.), Methods in Cellular Immunology, Freeman, San Francisco, 1980, pp. 138-151.
24. LaSalle J.M., Tolentino P.J., Freeman G.J., Nadler L.M., Hafler D.A. Early signaling defects in human T cells anergized by T cell presentation of autoantigen. J. Exp. Med. 176:1992;177-186.
25. Anderton S., Burkhart C., Metzler B., Wraith D. Mechanisms of central and peripheral T-cell tolerance lessons from experimental models of multiple sclerosis . Immunol. Rev. 169:1999;123-137.
26. Malvey E.N., Jenkins M.K., Mueller D.L. Peripheral immune tolerance blocks clonal expansion but fails to prevent the differentiation of Th1 cells. J. Immunol. 161:1998;2168-2177.
27. Liblau R., Tisch R., Bercovici N., McDevitt H.O. Systemic antigen in the treatment of T-cell-mediated autoimmune diseases. Immunol. Today. 18:1997;599-604.
28. Owen J.A., Allouche M., Doherty P.C. Limiting dilution analysis of the specificity of influenza-immune cytotoxic T cells. Cell. Immunol. 67:1982;49-59.
29. Brenner T., Arnon R., Sela M., Abramsky O., Meiner Z., Riven-Kreitman R., Tarcik N., Teitelbaum D. Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with Copaxone. J. Neuroimmunol. 115:2001;152-160.
30. Ragheb S., Abramczyk S., Lisak D., Lisak R. Long-term therapy with glatiramer acetate in multiple sclerosis effect on T-cells . Multiple Scler. 7:2001;43-47.
31. Rocha B., Tanchot C., Von Boehmer H. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J. Exp. Med. 177:1993;1517-1521.
32. Sprent J., Gao E.K., Webb S.R. T cell reactivity to MHC molecules immunity versus tolerance . Science. 248:1990;1357-1363.
33. Rocha B., Grandien A., Freitas A.A. Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance. J. Exp. Med. 181:1995;993-1003.
34. Gajewski T.F., Qian D., Fields P., Fitch F.W. Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc. Natl. Acad. Sci. USA. 91:1994;38-42.
35. Chai J.G., Bartok I., Chandler P., Vendetti S., Antoniou A., Dyson J., Lechler R. Anergic T cells act as suppressor cells in vitro and in vivo. Eur. J. Immunol. 29:1999;686-692.
36. Kipnis J., Yoles E., Porat Z., Cohen A., Mor F., Sela M., Cohen I.R., Schwartz M. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve possible therapy for optic neuropathies . Proc. Natl. Acad. Sci. USA. 97:2000;7446-7451.
37. Van Parijs L., Abbas A.K. Homeostasis and self-tolerance in the immune system turning lymphocytes off . Science. 280:1998;243-248.
38. Beverly B., Kang S.M., Lenardo M.J., Schwartz R.H. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int. Immunol. 4:1992;661-671.
39. Maier C.C., Greene M.I. Biochemical features of anergic T cells. Immunol. Res. 17:1998;133-140.
40. LaSalle J.M., Ota K., Hafler D.A. Presentation of autoantigen by human T cells. J. Immunol. 147:1991;774-780.
41. Sloan-Lancaster J., Evavold B.D., Allen P.M. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature. 363:1993;156-159.
42. Schwartz R.H. A cell culture model for T lymphocyte clonal anergy. Science. 248:1990;1349-1356.
43. LaSalle J.M., Hafler D.A. T cell anergy. FASEB J. 8:1994;601-608.
44. Wiesemann E., Klatt J., Sonmez D., Blasczyk R., Heidenreich F., Windhagen A. Glatiramer acetate (GA) induces IL-13/ IL-5 secretion in naive T cells. J. Neuroimmunol. 119:2001;137-144.
45. Sloan-Lancaster J., Evavold B.D., Allen P.M. Th2 cell clonal anergy as a consequence of partial activation. J. Exp. Med. 180:1994;1195-1205.